Literature DB >> 18193922

Office-based maintenance treatment of opioid dependence: how does it compare with traditional approaches?

Erik W Gunderson1, David A Fiellin.   

Abstract

The increasing global public health burden of heroin dependence and prescription opioid dependence warrants further expansion of treatment models. The most effective intervention for opioid dependence remains maintenance with methadone, a full mu-opioid receptor agonist, or buprenorphine, a partial mu-opioid receptor agonist.A growing body of evidence supports the use of opioid receptor agonist maintenance in office-based settings. Office-based opioid treatment (OBOT) can expand treatment access in a less stigmatized environment, which enables integrated care of co-morbid conditions. The current review primarily examines OBOT in the US, although a comparison with the British and French models is provided, given that the public health impact and implementation of OBOT will likely vary between countries because of policy and logistical differences. The comparative effectiveness of maintenance treatment in office-based and traditional programme-based models of care requires further study. Clinical and practical considerations when providing treatment for opioid dependence in traditional versus office-based settings include patient selection and monitoring, health economics, management of co-morbid conditions, and access to ancillary psychosocial treatment. OBOT is not a replacement for more structured, traditional models of care, but provides an additional opportunity to help address the tremendous public health impact of opioid dependence.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18193922     DOI: 10.2165/00023210-200822020-00002

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  84 in total

1.  Beliefs about methadone in an inner-city methadone clinic.

Authors:  Sharon Stancliff; Julie Elana Myers; Stuart Steiner; Ernest Drucker
Journal:  J Urban Health       Date:  2002-12       Impact factor: 3.671

2.  Short-term buprenorphine maintenance: treatment outcome.

Authors:  Marc Galanter; Helen Dermatis; Richard Resnick; Robert Maslansky; Erna Neumann
Journal:  J Addict Dis       Date:  2003

Review 3.  Clinical and pharmacological evaluation of buprenorphine and naloxone combinations: why the 4:1 ratio for treatment?

Authors:  John Mendelson; Reese T Jones
Journal:  Drug Alcohol Depend       Date:  2003-05-21       Impact factor: 4.492

4.  Are supplementary services provided during methadone maintenance really cost-effective?

Authors:  M K Kraft; A B Rothbard; T R Hadley; A T McLellan; D A Asch
Journal:  Am J Psychiatry       Date:  1997-09       Impact factor: 18.112

Review 5.  Brief report: Methadone treatment of injecting opioid users for prevention of HIV infection.

Authors:  Linda R Gowing; Michael Farrell; Reinhard Bornemann; Lynn E Sullivan; Robert L Ali
Journal:  J Gen Intern Med       Date:  2005-12-07       Impact factor: 5.128

6.  Imipramine treatment of opiate-dependent patients with depressive disorders. A placebo-controlled trial.

Authors:  E V Nunes; F M Quitkin; S J Donovan; D Deliyannides; K Ocepek-Welikson; T Koenig; R Brady; P J McGrath; G Woody
Journal:  Arch Gen Psychiatry       Date:  1998-02

7.  Methadone medical maintenance in primary care. An implementation evaluation.

Authors:  Joseph O Merrill; T Ron Jackson; Beryl A Schulman; Andrew J Saxon; Asaad Awan; Sonja Kapitan; Molly Carney; Lyndia C Brumback; Dennis Donovan
Journal:  J Gen Intern Med       Date:  2005-04       Impact factor: 5.128

8.  Buprenorphine versus methadone in the treatment of opioid-dependent cocaine users.

Authors:  E C Strain; M L Stitzer; I A Liebson; G E Bigelow
Journal:  Psychopharmacology (Berl)       Date:  1994-12       Impact factor: 4.530

9.  Outcomes of treatment of socially rehabilitated methadone maintenance patients in physicians' offices (medical maintenance): follow-up at three and a half to nine and a fourth years.

Authors:  D M Novick; H Joseph; E A Salsitz; M F Kalin; J B Keefe; E L Miller; B L Richman
Journal:  J Gen Intern Med       Date:  1994-03       Impact factor: 5.128

10.  Buprenorphine versus methadone maintenance: a cost-effectiveness analysis.

Authors:  Christopher M Doran; Marian Shanahan; Richard P Mattick; Robert Ali; Jason White; James Bell
Journal:  Drug Alcohol Depend       Date:  2003-09-10       Impact factor: 4.492

View more
  15 in total

1.  Therapeutic switch to buprenorphine/naloxone from buprenorphine alone: clinical experience in an Italian addiction centre.

Authors:  Franco Montesano; Domenico Zaccone; Egidio Battaglia; Felice Genco; Vincenzo Mellace
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

2.  Clinical experience with fortnightly buprenorphine/naloxone versus buprenorphine in Italy: preliminary observational data in an office-based setting.

Authors:  Patrizia Amato
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

3.  Improving temporal efficiency of outpatient buprenorphine induction.

Authors:  Erik W Gunderson; Frances R Levin; Margaret M Rombone; Suzanne K Vosburg; Herbert D Kleber
Journal:  Am J Addict       Date:  2011-07-18

4.  Emerging adult age status predicts poor buprenorphine treatment retention.

Authors:  Zev Schuman-Olivier; Roger D Weiss; Bettina B Hoeppner; Jacob Borodovsky; Mark J Albanese
Journal:  J Subst Abuse Treat       Date:  2014-05-20

5.  Buprenorphine for prescription opioid addiction in a patient with depression and alcohol dependence.

Authors:  Marc J Fishman; Li-Tzy Wu; George E Woody
Journal:  Am J Psychiatry       Date:  2011-07       Impact factor: 18.112

Review 6.  The Role of Behavioral Interventions in Buprenorphine Maintenance Treatment: A Review.

Authors:  Kathleen M Carroll; Roger D Weiss
Journal:  Am J Psychiatry       Date:  2016-12-16       Impact factor: 18.112

7.  Benzodiazepine use during buprenorphine treatment for opioid dependence: clinical and safety outcomes.

Authors:  Zev Schuman-Olivier; Bettina B Hoeppner; Roger D Weiss; Jacob Borodovsky; Howard J Shaffer; Mark J Albanese
Journal:  Drug Alcohol Depend       Date:  2013-05-18       Impact factor: 4.492

8.  High levels of opioid analgesic co-prescription among methadone maintenance treatment clients in British Columbia, Canada: results from a population-level retrospective cohort study.

Authors:  Bohdan Nosyk; Benedikt Fischer; Huiying Sun; David C Marsh; Thomas Kerr; Juergen T Rehm; Aslam H Anis
Journal:  Am J Addict       Date:  2014 May-Jun

9.  A call for evidence-based medical treatment of opioid dependence in the United States and Canada.

Authors:  Bohdan Nosyk; M Douglas Anglin; Suzanne Brissette; Thomas Kerr; David C Marsh; Bruce R Schackman; Evan Wood; Julio S G Montaner
Journal:  Health Aff (Millwood)       Date:  2013-08       Impact factor: 6.301

10.  Unobserved versus observed office buprenorphine/naloxone induction: a pilot randomized clinical trial.

Authors:  Erik W Gunderson; Xin-Qun Wang; David A Fiellin; Benjamin Bryan; Frances R Levin
Journal:  Addict Behav       Date:  2010-01-18       Impact factor: 3.913

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.